Maria Feldman
Keine laufenden Positionen mehr
Profil
Maria Feldman worked as Director of Regulatory Affairs at MediciNova, Inc., VP of Regulatory Affairs & Clinical Research at Neothetics, Inc., and VP of Clinical Research, Operations & Regulatory at Evofem Biosciences, Inc. She obtained an undergraduate degree from St. Olaf College.
Ehemalige bekannte Positionen von Maria Feldman
| Unternehmen | Position | Ende |
|---|---|---|
Neothetics, Inc.
 Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Geschäftsführer | - |
| EVOFEM BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| MEDICINOVA, INC. | General Counsel | - |
Ausbildung von Maria Feldman
| St. Olaf College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MEDICINOVA, INC. | Health Technology |
| EVOFEM BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Health Technology |
